Moore S - Search Results

1

Stem cell factor and chronic myeloid leukemia CD34+ cells.

Moore S, McDiarmid LA, Hughes TP. Moore S, et al. Leuk Lymphoma. 2000 Jul;38(3-4):211-20. doi: 10.3109/10428190009087013. Leuk Lymphoma. 2000. PMID: 10830729 Review.

2

The detection of Philadelphia chromosome negative metaphases in long-term bone marrow cultures of the peripheral blood from patients with chronic myeloid leukemia predicts response to interferon-alpha 2a.

Gronthos S, To LB, Moore S, Suttle JM, Juttner CA. Gronthos S, et al. Among authors: moore s. Leukemia. 1992 Dec;6(12):1246-9. Leukemia. 1992. PMID: 1453769

3

Detection of rearrangement within the breakpoint cluster region of chromosome 22 in the diagnosis of chronic myeloid leukemia.

Hutchins C, Casey G, White D, Moore S, Rudzki Z, Kimber R. Hutchins C, et al. Among authors: moore s. Aust N Z J Med. 1989 Oct;19(5):443-8. doi: 10.1111/j.1445-5994.1989.tb00302.x. Aust N Z J Med. 1989. PMID: 2590093

4

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.

Lewis ID, Haylock DN, Moore S, To LB, Hughes TP. Lewis ID, et al. Among authors: moore s. Leukemia. 1997 Apr;11(4):581-7. doi: 10.1038/sj.leu.2400604. Leukemia. 1997. PMID: 9096699

5

Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.

Moore S, Haylock DN, Lévesque JP, McDiarmid LA, Samels LM, To LB, Simmons PJ, Hughes TP. Moore S, et al. Blood. 1998 Oct 1;92(7):2461-70. Blood. 1998. PMID: 9746786 Free article.

6

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Ross DM, Branford S, Moore S, Hughes TP. Ross DM, et al. Among authors: moore s. Leukemia. 2006 Apr;20(4):664-70. doi: 10.1038/sj.leu.2404139. Leukemia. 2006. PMID: 16482210

7

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tang C, et al. Among authors: moore s. Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30. Leuk Lymphoma. 2011. PMID: 21718141

8

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan CG, Hughes TP, White DL. Yeung DT, et al. Among authors: moore s. Leukemia. 2015 Jan;29(1):230-2. doi: 10.1038/leu.2014.256. Epub 2014 Sep 2. Leukemia. 2015. PMID: 25179732 No abstract available.

9

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.

Ross DM, Altamura HK, Hahn CN, Nicola M, Yeoman AL, Holloway MR, Geoghegan J, Feng J, Schreiber AW, Branford S, Moore S, Scott HS. Ross DM, et al. Among authors: moore s. Leukemia. 2016 Jun;30(6):1402-5. doi: 10.1038/leu.2015.301. Epub 2015 Oct 27. Leukemia. 2016. PMID: 26503642 No abstract available.

10

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL. Sadras T, et al. Among authors: moore as, moore s. Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1. Cancer Lett. 2017. PMID: 28866095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,036 results

Search Page

Filters